T ranscatheter aortic valve replacement (TAVR) is now a common alternative to surgical valve replacement in high-risk patients with severe aortic stenosis. [1] [2] [3] [4] [5] [6] The short-term outcomes of TAVR have been well evaluated. However, because transcatheter valves only became available in 2007, and because of the particular high-risk profile of patients undergoing TAVR in the initial pivotal randomized trials and registries, data for long-term results and late valve performance are limited. 1, [7] [8] [9] The FRANCE-2 registry (French Aortic National CoreValve and Edwards), including all patients who underwent TAVR in all centers in France during a 2-year period, provides a unique opportunity to analyze 5-year clinical and echocardiographic results in a large real-world population.
METHODS

Registry
The design of the FRANCE 2 registry was previously described in the 1-and 3-year follow-up reports. 10, 11 Briefly, the registry includes all consecutive symptomatic patients (New York Heart Association class >II) with severe aortic stenosis (defined as valve area ≤0.8 cm 2 , mean valve gradient ≥40 mm Hg, or peak aortic jet velocity ≥4.0 m/s) who were found ineligible for surgical aortic valve replacement on heart team evaluation because of coexisting risk features. A total of 34 centers (all 33 French centers and 1 in Monaco) prospectively enrolled all patients undergoing TAVR between January 2010 and January 2012. All patients provided written informed consent for anonymous processing of their data, and the institutional review board of the French Ministry of Health approved the registry. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure, as it is the property of the French Society of Cardiology. The STROBE checklist (Strengthening the Reporting of Observational Studies in Epidemiology) is presented in the supplemental material (Table I in the online-only Data Supplement).
TAVR Procedure and Devices
All patients received either a self-expandable device (CoreValve ReValving System, Medtronic, Minneapolis, MN) or a balloon-expandable device (Edwards SAPIEN or SAPIEN XT prosthesis, Edwards Lifesciences, Irvine, CA). Choice of prosthesis, approach (transfemoral, transapical, or subclavian), and anesthesia (general or local) was at the operator's discretion. Antithrombotic therapy comprised aspirin (≤160 mg once daily) and clopidogrel (300 mg loading dose, then 75 mg once daily) before the procedure, followed by 1 month of dual therapy, then aspirin alone.
Study End Points, Definitions, and Follow-Up
The primary end point was all-cause mortality at 1 month, 6 months, and 1, 2, 3, 4, and 5 years. The secondary safety end points were major adverse cardiovascular or cerebrovascular events, cardiac events, cardiac or vascular surgery, bleeding or stroke, and New York Heart Association functional status. The secondary efficacy end points were success rate and complications on the Valve Academic Research Consortium criteria. 12 Follow-up was included in the protocol, with consultations recording clinical status, events, and echocardiography at 1 month, 6 months and 1, 2, 3, 4, and 5 years. Valve function was assessed in terms of mean gradient, valve area, and presence and severity of aortic or mitral regurgitation (graded from 0 to 4, with higher grades indicating greater severity). Hemodynamic structural valve deterioration (SVD) was defined according the consensus statement by the European Association of Percutaneous Cardiovascular Interventions. 13 Moderate hemodynamic SVD included any of the following: mean gradient ≥20 and <40 mm Hg, or ≥10 and <20 mm Hg mean gradient change from 1-month postprocedural baseline, or moderate central aortic regurgitation (AR) or new AR or worsening with respect to baseline (grade 2, 3, or 4). Severe hemodynamic SVD included any of the following: mean gradient ≥40 mm Hg, or ≥20 mm Hg increase in mean gradient with respect to 1-month postprocedural baseline, or moderate central AR, new AR, or worsening with respect to baseline (grade 3 or 4).
Data Management
All adverse events were adjudicated according to the Valve Academic Research Consortium classification system 12 ; mortality was adjudicated by an independent committee (online-only Data Supplement, Table II in the online-only Data Supplement). Data were recorded on a standardized electronic case-report form and sent over the internet to a central database (Axonal). Database quality control was performed by checking data against source documents for 10% of patients in randomly selected centers. All fields were examined for missing data or outliers, and teams were asked to complete or correct data wherever possible. Outlying data were checked and excluded if erroneous; exclusion concerned less than 1% of the data.
Clinical Perspective
What Is New? Nonfatal clinical events were not analyzed using the Kaplan-Meier method, as repeated events may occur in a given patient. All events were taken into account, and the corresponding percentages were calculated by dividing the total number of events by the estimated number of patients exposed in each time period. To take account of competing risk of death, severe SVD and moderate/severe SVD were analyzed using a cumulative incidence function. In addition, mean gradients and valve areas were presented in paired analyses for all time points after implantation. All analyses used SAS software, version 9.2 (SAS Institute, Cary, NC).
RESULTS
Overall, 4201 consecutive patients were treated by TAVR in 34 hospitals and included in the FRANCE-2 registry between January 2010 and January 2012 (Table  II in the online-only Data Supplement). Procedural and patient characteristics and initial and 3-year results were previously published. 10, 11 The baseline characteristics of patients are reported in Table 1 . Briefly, a balloonexpandable prosthesis was implanted in 2774 patients (66.0%), a self-expandable prosthesis in 1413 (33.7%), and in 14 patients (0.3%), the type of valve was not recorded. The TAVR approach was mainly transfemoral (3064 patients; 72.9%). Nonfemoral approaches were transapical (17.5%: 735 patients), subclavian (5.8%: 242 patients), or other (transaortic or transcarotid) (3.2%: 134 patients); in 0.6% of cases (26 patients), the approach was not recorded. Procedures were performed under local anesthesia for 42.7% of the femoral approaches. Mean hospital stay was 11.5±13.0 days. Procedural success rate was 97.2%.
Outcomes
Mortality At 5 years, vital status was available for 4010 patients (95.5%), and 3699 patients (88.1%) had clinical evaluation or had died. The scheduled 5-year consultation was performed before 60 months in 401 patients, including 339 between 57 and 60 months. All-cause mortality was 23.3% (n=974) at 1 year (95% CI, 22.0% to 24.6%), 33.1% (n=1379) at 2 years (95% CI, 31.5% to 34.3%), 42.5% (n=1763) at 3 years (95% CI, 40.5% to 43.5%), 52.3% (n=2154) at 4 years (95% CI, 50.7% to 53.8%), and 60.8% (n=2478) at 5 years (95% CI, 59.3% to 62.3%; Figure 1A ). According to logistic EuroSCORE, all-cause mortality is higher in extreme/highrisk patients (≥20%) as compared with intermediateand low-risk patients ( Figure 1B) .
Mortality was systematically lower throughout follow-up in patients undergoing TAVR via a transfemoral approach than for other approaches (online-only Data Supplement, Table III in the online-only Data Supplement). At 5 years, all-cause mortality reached 59.0% (n=1754) for transfemoral, 66.2% (n=470) for transapical, and 66.2% (n=158) for subclavian approaches. 
ORIGINAL RESEARCH ARTICLE
Clinical Events
The majority of cardiovascular events occurred in the first month after valve replacement, and incidence remained low thereafter, at <2% per year up to 5 years, except for heart failure ( Figure 2 ). The most frequent complication was implantation of a new pacemaker, Figure 4A and 4B and Table 2 . Echocardiographic evaluation of valve performance in patients who had echocardiographic measurements for all time points up to 5 years is shown in supplemental material ( Figure IA and IB in the online-only Data Supplement). Periprosthetic AR≥2 was systematically associated with higher mortality than for AR=0 to 1 up to 5 years (hazard ratio, Figure 5 ). The frequency of moderate and severe hemodynamic SVD according to European Association of Percutaneous Cardiovascular Interventions criteria is represented in Table 2 for each year of follow-up. Moderate SVD occurred in 6.9% of patients with echocardiographic evaluation available at 1 year and in 12.4% between 4 and 5 years, and severe SVD in 1.4% at 1 year and 2.9% between 4 and 5 years. Numbers and percentages of moderate and severe SVD over time are presented in Table 2 according to type of prosthesis. Overall, 60 patients showed severe SVD at 5 years; among those, 30 (50.0%) were defined as severe SVD by a gradients ≥40 mm Hg, 22 (36.7%) by ≥20 mm Hg change from baseline, and 12 (23.5%) defined by the presence of severe intraprothetic AR ≥2. Twelve patients (20.0%) with severe SVD had been previously classified as having moderate SVD. In addition, mean valve area in this specific population was 1.53±0.87 cm 2 . Mortality did not differ between patients with or without severe SVD (hazard ratio, 0.71; 95% CI, 0.47-1.07; P=0.1). Finally, in severe SVD, 1 patient (1.7%) experienced stroke, and 8 presented with ≥1 heart failure event (13.3%). In cumulative incidence function, the rates of severe SVD and moderate/severe SVD at 5 years were 2.5% and 13.3%, respectively (Figure 6 ). The frequency of severe SVD, according valve size for balloon-expandable valves, was 22 (52.4%) for the 23-mm valve, 18 (42.9%) for the 26-mm valve, and 2 
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Circulation. Figure 7 shows the cumulative incidence function of severe SVD according to type of valve.
DISCUSSION
The present 5-year follow-up results from the FRANCE-2 registry describe long-term clinical and echocardiographic outcomes in the largest cohort of consecutive TAVR patients with available late follow-up. The high levels of knowledge of vital status (95.5%) and events (88.1%) enable accurate 5-year evaluation of patients who underwent TAVR. Echocardiographic evaluation performed in several hundred patients at 5 years provides unique information with regard to valve durability. ORIGINAL RESEARCH ARTICLE mortality primarily cardiovascular (Figure 1 ). The rate of 5-year all-cause mortality (60.8%) in the FRANCE-2 registry was in line with the 5-year results of the Placement of Aortic Transcatheter Valves trial (PARTNER 1) in 348 severe aortic stenosis patients, which reported slightly higher incidence, with 67.8% all-cause mortality, explained by their learning curve between 2007 and 2010. 1 The Italian registry, comprising 353 patients (108 with 5 years of follow-up) undergoing TAVR with a self-expandable device reported 55% all-cause mortality. 12 In the UK registry, all-cause mortality was 53.1%, although only 160 patients were followed up for 5 years. 9 The Canadian registry, with 88 patients (29 with 5 years of follow-up) with balloon-expandable devices, reported 65% all-cause mortality. 
Long-Term Clinical Outcomes
Clinical Events
In the FRANCE-2 registry, clinical events, as previously reported, 10, 11 occurred mainly during the first month, with incidence remaining low (<2%) from 2 to 5 years (Figure 2 ). This initial extra risk after TAVR may be the price of the procedure. The development of the second generation of valves, with better profile (smaller size, hydrophilic sheaths) and features to further reduce periprosthetic AR, could reduce these early postprocedural complications. 8, 14 In addition, functional status was maintained up to 5 years, with >88% of patients showing New York Heart Association class ≤II. At 1 year, the rate of heart failure was 14.3%. This high rate of heart failure illustrates that it has a multifactorial origin and is not always prevented by treating aortic stenosis. This should be interpreted in the light of high rates of hypertension, coronary artery disease, and severe symptoms attesting, to advanced consequences of aortic stenosis. An even higher 1-year heart failure rate of 24.1% was reported by Durand et al. 15 The impact of heart failure on 5-year mortality in the FRANCE-2 registry can be seen in the rates of 57.7% mortality without heart failure versus 67.8% with heart failure, consistent with the findings of Durand et al. 15 The annual rate of heart failure markedly decreased to <5% after 1 year in the FRANCE-2 registry. No other data are available in the literature beyond 1 year. This may be attributable to late left ventricular remodeling, but also to premature death from early recurrence of heart failure after TAVR. Long-term data on self-expandable valves are provided by the pivotal CoreValve randomized, controlled trial, 2 also reporting stable gradients and valve area, although at only 3 years of follow-up in 190 patients. The Italian Registry confirmed these data, with only 4.2% SVD in 108 patients at 5 years. 8 The UK registry provided exclusively clinical 5-year data without any late assessment of valve function on echocardiography.
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The FRANCE-2 registry is therefore the largest cohort available, with 459 patients having echocardiographic evaluation at 5 years. The findings demonstrated good durability for both types of transcatheter bioprosthesis, with 2.5% severe SVD in cumulative incidence function at 5 years ( Figure 6 ), according to the recent European Association of Percutaneous Cardiovascular Interventions definition. In addition, although the data on severe SVD should be interpreted with caution because of the small number of patients available, the presence of severe SVD did not seem to be associated with excess mortality. One possible explanation is that the majority of cases of severe SVD are defined by an increased or high mean gradient rather than by the presence of severe AR. In fact, because many factors can influence valve area measurement, an increase in mean gradient ). Nevertheless, patients with severe SVD did show frequent heart failure events. Although no conclusions could be drawn, SVD appeared more frequent in small valve sizes as compared with the largest valves, which could again be mainly attributable to classification of severe SVD by an increase in mean gradient. Finally, cumulative incidence functions of severe SVD between types of valve did not differ (Figure 7) .
The European Association of Percutaneous Cardiovascular Interventions consensus now standardizes the definition of SVD for all surgical and transcatheter valves. However, this raises the difficulty of comparing the real incidence of SVD between the 2 types of bioprosthesis. In surgical bioprostheses, where SVD is frequently related to severe stenosis or regurgitation, the expected incidence is <10% at 10 years. [17] [18] [19] Two potential factors could directly affect late and very late results for TAVR: bioprosthesis durability and the patient's comorbidities. The present study and the current data on transcatheter valves do not show any signs of medium-term transcatheter valve degeneration in highrisk patients in terms of endocarditis or major structural valve failure. 1, 7, 8, 18, [20] [21] [22] 
Study Limitations
This study had limitations that need to be taken into consideration. First, clinical events were declared by the participating centers and not independently adjudicated. However, only major events according to the Valve Academic Research Consortium classification were reported, which would not tend to be underreported during long-term follow-up. Moreover, the accuracy of the heart failure rate may be uncertain, because this event is not part of the Valve Academic Research Consortium classification; nevertheless, the clinical importance of this event, often leading to hospital admission, would suggest accurate reporting. Estimated mortality, on the other hand, was highly reliable, as vital status was available and adjudicated in 95.5% of cases at 5 years. Second, the lack of systematic core laboratory evaluation for echocardiographic assessment was another limitation, specifically for the identification and quantification of central and/or periprosthetic AR.
Late echocardiographic follow-up was not available in all surviving patients. However, only age and sex differed between patients with and without echocardiographic assessment at 5 years, whereas EuroSCORE did not differ, suggesting limited bias (online-only Data Supplement, Table III in the online-only Data Supplement). Older age in patients without echocardiography evaluation reflects the difficulty of performing systematic investigations in elderly patients with comorbidities. However, the present findings, obtained in >450 patients at 5 years, represent by far the largest data set on the durability of TAVR prostheses. 
